Literature DB >> 20980515

Reverse genetics generation of chimeric infectious Junin/Lassa virus is dependent on interaction of homologous glycoprotein stable signal peptide and G2 cytoplasmic domains.

César G Albariño1, Brian H Bird, Ayan K Chakrabarti, Kimberly A Dodd, David M White, Eric Bergeron, Punya Shrivastava-Ranjan, Stuart T Nichol.   

Abstract

The Arenaviridae are a diverse and globally distributed collection of viruses that are maintained primarily by rodent reservoirs. Junin virus (JUNV) and Lassa virus (LASV) can both cause significant outbreaks of severe and often fatal human disease throughout their respective areas of endemicity. In an effort to improve upon the existing live attenuated JUNV Candid1 vaccine, we generated a genetically homogenous stock of this virus from cDNA copies of the virus S and L segments by using a reverse genetics system. Further, these cDNAs were used in combination with LASV cDNAs to successfully generate two recombinant Candid1 JUNV/LASV chimeric viruses (via envelope glycoprotein [GPC] exchange). It was found that while the GPC extravirion domains were readily exchangeable, homologous stable signal peptide (SSP) and G2 transmembrane and cytoplasmic tail domains were essential for correct GPC maturation and production of infectious chimeric viruses. The switching of the JUNV and LASV G1/G2 ectodomains within the Candid1 vaccine background did not alter the attenuated phenotype of the vaccine strain in a lethal mouse model. These recombinant chimeric viruses shed light on the fundamental requirements of arenavirus GPC maturation and may serve as a strategy for the development of bivalent JUNV and LASV vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20980515      PMCID: PMC3014187          DOI: 10.1128/JVI.01837-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies.

Authors:  Mar Perez; Rebecca C Craven; Juan C de la Torre
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-16       Impact factor: 11.205

2.  Signal peptide of Lassa virus glycoprotein GP-C exhibits an unusual length.

Authors:  Robert Eichler; Oliver Lenz; Thomas Strecker; Wolfgang Garten
Journal:  FEBS Lett       Date:  2003-03-13       Impact factor: 4.124

3.  Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles [corrected].

Authors:  Thomas Strecker; Robert Eichler; Jan ter Meulen; Winfried Weissenhorn; Hans Dieter Klenk; Wolfgang Garten; Oliver Lenz
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

4.  Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses.

Authors:  Siddhartha Mahanty; Karen Hutchinson; Sudhanshu Agarwal; Michael McRae; Pierre E Rollin; Bali Pulendran
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

5.  Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever.

Authors:  S P Fisher-Hoch; S W Mitchell; D R Sasso; J V Lange; R Ramsey; J B McCormick
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

6.  Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone.

Authors:  T P Monath; V F Newhouse; G E Kemp; H W Setzer; A Cacciapuoti
Journal:  Science       Date:  1974-07-19       Impact factor: 47.728

7.  Mechanisms for lymphocytic choriomeningitis virus glycoprotein cleavage, transport, and incorporation into virions.

Authors:  Stefan Kunz; Kurt H Edelmann; Juan-Carlos de la Torre; Robert Gorney; Michael B A Oldstone
Journal:  Virology       Date:  2003-09-15       Impact factor: 3.616

8.  Hematologic dysfunction in Lassa fever.

Authors:  S Fisher-Hoch; J B McCormick; D Sasso; R B Craven
Journal:  J Med Virol       Date:  1988-10       Impact factor: 2.327

9.  Lassa fever. Effective therapy with ribavirin.

Authors:  J B McCormick; I J King; P A Webb; C L Scribner; R B Craven; K M Johnson; L H Elliott; R Belmont-Williams
Journal:  N Engl J Med       Date:  1986-01-02       Impact factor: 91.245

10.  Characterization of the Lassa virus matrix protein Z: electron microscopic study of virus-like particles and interaction with the nucleoprotein (NP).

Authors:  Robert Eichler; Thomas Strecker; Larissa Kolesnikova; Jan ter Meulen; Winfried Weissenhorn; Stephan Becker; Hans Dieter Klenk; Wolfgang Garten; Oliver Lenz
Journal:  Virus Res       Date:  2004-03-15       Impact factor: 3.303

View more
  25 in total

1.  Dissection of the role of the stable signal peptide of the arenavirus envelope glycoprotein in membrane fusion.

Authors:  Emily L Messina; Joanne York; Jack H Nunberg
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

2.  Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages.

Authors:  Xavier Carnec; Sylvain Baize; Stéphanie Reynard; Laure Diancourt; Valérie Caro; Noel Tordo; Michèle Bouloy
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

3.  The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain.

Authors:  César G Albariño; Brian H Bird; Ayan K Chakrabarti; Kimberly A Dodd; Mike Flint; Eric Bergeron; David M White; Stuart T Nichol
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

4.  Junin virus infects mouse cells and induces innate immune responses.

Authors:  Christian D Cuevas; Madakasira Lavanya; Enxiu Wang; Susan R Ross
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

5.  Biological Characterization of Conserved Residues within the Cytoplasmic Tail of the Pichinde Arenaviral Glycoprotein Subunit 2 (GP2).

Authors:  Hinh Ly; Yuying Liang; Junjie Shao; Qinfeng Huang; Xiaoying Liu; Da Di; Mythili Dileepan; Morgan Brisse
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

6.  Arenavirus reverse genetics for vaccine development.

Authors:  Emilio Ortiz-Riaño; Benson Yee Hin Cheng; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Gen Virol       Date:  2013-01-30       Impact factor: 3.891

7.  Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and live-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease.

Authors:  Sebastien F Emonet; Alexey V Seregin; Nadezhda E Yun; Allison L Poussard; Aida G Walker; Juan C de la Torre; Slobodan Paessler
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

Review 8.  Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses.

Authors:  Sheli R Radoshitzky; Jens H Kuhn; Fabian de Kok-Mercado; Peter B Jahrling; Sina Bavari
Journal:  Expert Opin Drug Discov       Date:  2012-05-19       Impact factor: 6.098

Review 9.  Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses.

Authors:  Thomas Hoenen; Allison Groseth; Fabian de Kok-Mercado; Jens H Kuhn; Victoria Wahl-Jensen
Journal:  Antiviral Res       Date:  2011-06-14       Impact factor: 5.970

Review 10.  Structure-function relationship of the mammarenavirus envelope glycoprotein.

Authors:  Wei Wang; Zheng Zhou; Leike Zhang; Shaobo Wang; Gengfu Xiao
Journal:  Virol Sin       Date:  2016-08-04       Impact factor: 4.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.